{
    "nct_id": "NCT04419649",
    "official_title": "A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)",
    "inclusion_criteria": "1. Diagnosis of MDS according to World Health Organization (WHO)/French American British (FAB) classification that meets Revised International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate risk disease.\n2. < 5% blasts in bone marrow.\n3. Peripheral blood white blood cell count <13,000/µL.\n4. Anemia defined as:\n\n   1. In non-transfused participants, having received no red blood cell (RBC) transfusions within 8 weeks Hgb concentration ≤ 10.0 g/dL OR\n   2. In LTB participants, having received 1 to 3 units RBCs for Hgb ≤ 9.0 g/dL within 8 weeks OR\n   3. In HTB participants, having received ≥ 4 units of RBCs for Hgb ≤ 9.0 g/dL within 8 weeks\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (if related to anemia.\n6. Females of child-bearing potential and sexually active males must agree to use effective methods of contraception.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Any active infection requiring parenteral antibiotic therapy within 28 days prior to Cycle 1 Day 1 or oral antibiotics within 14 days of Cycle 1 Day 1.\n2. Diagnosis of secondary MDS (i.e., MDS known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).\n3. Vitamin B12 deficiency.\n4. Prior treatment with azacitidine, decitabine, lenalidomide, luspatercept, or sotatercept.\n5. Treatment within 28 days prior to Cycle 1 Day 1 with:\n\n   1. Erythropoiesis stimulating agent (ESA) OR\n   2. Granulocyte colony-stimulating factor (G-CSF) OR\n   3. Granulocyte-macrophage colony-stimulating factor (GM-CSF)\n6. Iron chelation therapy if initiated within 8 weeks prior to Cycle 1 Day 1.\n7. Vitamin B12 therapy within 8 weeks prior to Cycle 1 Day 1.\n8. Treatment with another investigational drug or device or approved therapy for investigational use < or = 28 days prior to Cycle 1 Day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to Cycle 1 Day 1, whichever is longer.\n9. Platelet count > 450 x 10*9/L or < 30 x 10*9/L.\n10. Transferrin saturation < 15%.\n11. Ferritin < 50 µg/L.\n12. Folate < 4.5 nmol/L (< 2.0 ng/mL).\n13. Vitamin B12 < 148 pmol/L (< 200 pg/mL).\n14. Estimated glomerular filtration rate (GFR) < 40 mL/min/1.73 m2 (as determined by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI].\n15. Pregnant or lactating females",
    "miscellaneous_criteria": "Key"
}